Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Income (2019 - 2025)

Revolution Medicines has reported Net Income over the past 7 years, most recently at -$364.9 million for Q4 2025.

  • Quarterly results put Net Income at -$364.9 million for Q4 2025, down 189.99% from a year ago — trailing twelve months through Dec 2025 was -$1.1 billion (down 3232188.57% YoY), and the annual figure for FY2025 was -$1.1 billion, down 3232188.57%.
  • Net Income for Q4 2025 was -$364.9 million at Revolution Medicines, down from -$305.2 million in the prior quarter.
  • Over the last five years, Net Income for RVMD hit a ceiling of $405.5 million in Q4 2024 and a floor of -$364.9 million in Q4 2025.
  • Median Net Income over the past 5 years was -$85.8 million (2022), compared with a mean of -$100.4 million.
  • Biggest five-year swings in Net Income: crashed 190.52% in 2023 and later soared 345.18% in 2024.
  • Revolution Medicines' Net Income stood at -$52.7 million in 2021, then decreased by 8.07% to -$56.9 million in 2022, then tumbled by 190.52% to -$165.4 million in 2023, then soared by 345.18% to $405.5 million in 2024, then crashed by 189.99% to -$364.9 million in 2025.
  • The last three reported values for Net Income were -$364.9 million (Q4 2025), -$305.2 million (Q3 2025), and -$247.8 million (Q2 2025) per Business Quant data.